144 related articles for article (PubMed ID: 11180765)
61. Developing a cell line standard for HER2/neu.
Rhodes A
Cancer Biomark; 2005; 1(4-5):229-32. PubMed ID: 17192046
[TBL] [Abstract][Full Text] [Related]
62. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].
Di Cosimo S; Baselga J
Nat Rev Clin Oncol; 2010 Mar; 7(3):139-47. PubMed ID: 20125090
[TBL] [Abstract][Full Text] [Related]
63. The biology of human epidermal growth factor receptor 2.
Sundaresan S; Penuel E; Sliwkowski MX
Curr Oncol Rep; 1999 Sep; 1(1):16-22. PubMed ID: 11122793
[TBL] [Abstract][Full Text] [Related]
64. Clinicopathologic features and treatment advances in cancers with HER2 alterations.
Cen S; Liu Z; Pan H; Han W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188605. PubMed ID: 34358635
[TBL] [Abstract][Full Text] [Related]
65. Her-2/neu as a paradigm of a tumor-specific target for therapy.
Choudhury A; Kiessling R
Breast Dis; 2004; 20():25-31. PubMed ID: 15687704
[TBL] [Abstract][Full Text] [Related]
66. A review of HER2 overexpression and somatic mutations in cancers.
Galogre M; Rodin D; Pyatnitskiy M; Mackelprang M; Koman I
Crit Rev Oncol Hematol; 2023 Jun; 186():103997. PubMed ID: 37062337
[TBL] [Abstract][Full Text] [Related]
67. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.
Olayioye MA
Breast Cancer Res; 2001; 3(6):385-9. PubMed ID: 11737890
[TBL] [Abstract][Full Text] [Related]
68. HER2/neu: a target for breast cancer therapy.
Zwick E; Wallasch C; Ullrich A
Breast Dis; 2000; 11():7-18. PubMed ID: 15687589
[TBL] [Abstract][Full Text] [Related]
69. Working together for the family: determination of HER oncogene co-amplifications in breast cancer.
Laurito S; Branham MT; Campoy E; Real S; Cueto J; Urrutia G; Gago F; Tello O; Glatstein T; De la Iglesia P; Atanesyan L; Savola S; Roqué M
Oncotarget; 2020 Jul; 11(28):2774-2792. PubMed ID: 32733648
[TBL] [Abstract][Full Text] [Related]
70. Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.
MacNeil IA; Khan SA; Sen A; Soltani SM; Burns DJ; Sullivan BF; Laing LG
Cell Commun Signal; 2022 Jan; 20(1):4. PubMed ID: 34998412
[TBL] [Abstract][Full Text] [Related]
71. What is HER2?
Cooke T
Eur J Oncol Nurs; 2000 Mar; 4(Sa):2-9. PubMed ID: 12849611
[TBL] [Abstract][Full Text] [Related]
72. HER2 status and breast cancer therapy: recent advances.
Tripathy D
F1000 Med Rep; 2009 Mar; 1():. PubMed ID: 20948761
[TBL] [Abstract][Full Text] [Related]
73. Corrigendum to 'The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer' [European Journal of Cancer 154 (2021) 175-189].
Le Du F; Dièras V; Curigliano G
Eur J Cancer; 2021 Nov; 158():255. PubMed ID: 34666920
[No Abstract] [Full Text] [Related]
74. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
75. Anti-salivary antibodies in primary Sjögren's syndrome.
Atkinson JC; Royce LS; Wellner R; Pillemer SR; Bermudez D; Fox PC
J Oral Pathol Med; 1995 May; 24(5):206-12. PubMed ID: 7616459
[TBL] [Abstract][Full Text] [Related]
76. HER2 in breast cancer: a review and update.
Krishnamurti U; Silverman JF
Adv Anat Pathol; 2014 Mar; 21(2):100-7. PubMed ID: 24508693
[TBL] [Abstract][Full Text] [Related]
77. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
[TBL] [Abstract][Full Text] [Related]
78. Management of bloody nipple discharge.
Vargas HI; Romero L; Chlebowski RT
Curr Treat Options Oncol; 2002 Apr; 3(2):157-61. PubMed ID: 12057078
[TBL] [Abstract][Full Text] [Related]
79. Courvoisier's law revisited.
Memon AA; Soomro MI; Soomro QA
J Coll Physicians Surg Pak; 2012 Jun; 22(6):392-4. PubMed ID: 22630101
[TBL] [Abstract][Full Text] [Related]
80. Pathophysiology of myasthenia gravis.
Hughes BW; Moro De Casillas ML; Kaminski HJ
Semin Neurol; 2004 Mar; 24(1):21-30. PubMed ID: 15229789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
